Novel Function of Osteoprotegerin in the Modulation of Glucose Metabolism in the Liver via mTORC1
Diabetes · 2025
DOI: 10.2337/db25-0207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Sheng Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Liver, Glucose, Osteoprotegerin, TOR Serine-Threonine Kinases. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project, State Administration of Traditional Chinese Medicine of the People's Republic of China.
Abstract (Originalsprache)
Osteoprotegerin (OPG) has emerged as a pivotal factor in metabolic disease pathology; however, its role in hepatic glucose metabolism remains poorly understood. We demonstrated a pronounced reduction in hepatic OPG expression in obese mice, attributable to DNA hypermethylation mediated by DNMT3α. Opg overexpression in the liver reduced the basal metabolic rate and exacerbated glucose metabolism disorders in mice with high-fat diet–induced obesity, whereas Opg knockout yielded opposite effects. Furthermore, mammalian target of rapamycin complex 1 (mTORC1; Raptor)/S6K1/IRS1/AKT signaling was found to be required for the regulation of hepatic glucose metabolism. Mechanistic investigations revealed that OPG interacts with Raptor within the mTORC1 complex, facilitating its phosphorylation at Ser863 and Ser877, influencing the mTORC1 (Raptor)/S6K1/IRS1/AKT signaling pathway, and thereby affecting glucose metabolism and insulin sensitivity. These findings underscore the integral role of OPG in glucose homeostasis and suggest it as a novel therapeutic target in type 2 diabetes. Article Highlights Methylation of the Opg promoter inhibits hepatic OPG expression in obese mice. Hepatic OPG regulates glucose metabolism and insulin sensitivity in obese mice. OPG regulates glucose metabolism through interaction with mammalian target of rapamycin complex 1 (Raptor). Opg deficiency in mice reduces age-related metabolic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
- Department of Clinical Biochemistry and Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education, Chongqing Medical University, Chongqing, China.
- Department of Endocrinology, People's Hospital of Dazu, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Sheng Qiu, Ke Li, Dongfang Liu, Qinan Wu, Mengliu Yang
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project
- State Administration of Traditional Chinese Medicine of the People's Republic of China
- the General project of Chongqing Natural Science Foundation
Zitieren
APA
Qiu, S., Wang, X., Li, K., Zhang, S., Lai, Y., Mi, Q., Yang, M., Liu, D., Li, L., Wu, Q., & Yang, M. (2025). Novel Function of Osteoprotegerin in the Modulation of Glucose Metabolism in the Liver via mTORC1. Diabetes. https://doi.org/10.2337/db25-0207
Vancouver
Qiu S, Wang X, Li K, Zhang S, Lai Y, Mi Q, et al. Novel Function of Osteoprotegerin in the Modulation of Glucose Metabolism in the Liver via mTORC1. Diabetes. 2025. doi:10.2337/db25-0207
BibTeX
@article{Qiu2025,
author = {Qiu, Sheng and Wang, Xia and Li, Ke and Zhang, Siliang and Lai, Yerui and Mi, Qiao and Yang, Min and Liu, Dongfang and Li, Ling and Wu, Qinan and Yang, Mengliu},
title = {Novel Function of Osteoprotegerin in the Modulation of Glucose Metabolism in the Liver via mTORC1},
journal = {Diabetes},
year = {2025},
doi = {10.2337/db25-0207}
}
EUVIMED